Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells

Fett, James W.; Strydom, Daniël J.; Lobb, Roy R.; Alderman, Edward M.; Bethune, J. L.; Riordan, James; Vallée, Bert L.

doi:10.1021/bi00341a030

Cited by 887 publications

(615 citation statements)

References 34 publications

Supporting

Mentioning

596

Contrasting

Unclassified

Order By: Relevance

“…Growth factor Esch et al (1985) Basic fibroblast growth factor (bFGF) or Wilting et al (1991) Fibroblast growth factor-2 (FGF-2) Olivo et al (1992) Ribatti et al (1995) Fett et al (1985 Angiogenin Wilting et al (1991) Olivo et al (1992 Leibovich et al (1987) Tumor necrosis factor alpha (TNF-␣) Olivo et al (1992) Yang andMoses (1990) Transforming growth factor beta (TGF-␤) Wilting et al (1992) Platelet derived growth factor (PDGF) Wilting et al (1992Wilting et al ( , 1993 Vascular endothelial growth factor (VEGF) Ziche et al (1997) Placenta growth factor-1 (PIGF-1) Bouloumie et al (1998) Leptin Ribatti et al (2001 Erythropoietin (EPO) Ramoshebi and Ripamonti (2000) Osteogenic protein-1 (OP-1) Bernardini et al (2000) CC chemokine I-309…”

Section: Authorsmentioning

confidence: 99%

Chorioallantoic membrane capillary bed: A useful target for studying angiogenesis and anti‐angiogenesis in vivo

et al. 2001

View full text Add to dashboard Cite

The chick embryo chorioallantoic membrane (CAM) is an extraembryonic membrane that is commonly used in vivo to study both angiogenesis and anti-angiogenesis. This review 1) summarizes the current knowledge about the structure of the CAM's capillary bed; 2) discusses the controversy about the existence of a single blood sinus or a capillary plexus underlying the chorionic epithelium; 3) describes a new model of the CAM vascular growth, namely the intussusceptive mode; 4) reports findings regarding the role played by endogenous fibroblast growth factor-2 in CAM vascularization; and 5) addresses the use and limitations of the CAM as a model for studying angiogenesis and anti-angiogenesis. Anat Rec 264: [317][318][319][320][321][322][323][324] 2001.

show abstract

Section: Authorsmentioning

confidence: 99%

Chorioallantoic membrane capillary bed: A useful target for studying angiogenesis and anti‐angiogenesis in vivo

et al. 2001

View full text Add to dashboard Cite

show abstract

“…This process is essential in tissue growth and regeneration. Several factors are able to stimulate vascular endothelial cell growth, including fibroblast growth factor (FGF) [ 10], angiogenin [7], transforming growth factor beta (TGF-beta) [25], platelet derived growth factor (PDGF) [26] and vascular endothelial growth factor (VEGF) [2, 4, 1 !, 16].…”

Section: Introductionmentioning

confidence: 99%

Platelet-derived growth factor and vascular endothelial growth factor expression in disc herniation tissue: an immunohistochemical study

et al. 1997

View full text Add to dashboard Cite

“…Angiogenic factors, such as angiogenin (Ang), 6 fibroblast growth factor (FGF) 7 and vascular endothelial growth factor (VEGF), 8,9 have been demonstrated to play very important roles in angiogenesis. Ang was originally purified from human tumor cell conditioned medium, and later from human plasma on the basis of its capacity to induce neovascularization.…”

mentioning

confidence: 99%

Anti-tumor effect of hematopoietic cells carrying the gene of ribonuclease inhibitor

Chen

Tian

et al. 2004

Cancer Gene Ther

View full text Add to dashboard Cite

Human ribonuclease inhibitor (hRI) is an acid protein with a molecular weight of 50 kDa. It can inhibit the activity of pancreatic RNase (RNase A). Angiogenin (Ang) is a member of the ribonuclease super family. It has 35% identity with RNase A and contains ribonucleolytic activity. The substrate specificity of angiogenin seems, however, to be more restricted than that of the pancreatic RNase. Since Ang is an important angiogenic factor and RI is a highly efficient inhibitor of Ang, it can be hypothesized that RI may be a latent antiangiogenic drug. This study focuses on the feasibility of transfecting the ri gene into mice hematopoietic cells and inducing the expression of the ri gene to block the angiogenesis of solid tumors. First, the cDNA gene of the ri from human placenta was cloned and inserted in a retroviral vector, pLNCX. The combined vector pLNCX-ri was transfected into retroviral packaging cells, PA317, and a clone producing a high titer of virus was obtained. Next, isolated hematopoietic cells from mice bone marrow were infected with viruses carrying the pLNCX-ri. The infected cells were then injected into lethally irradiated mice. The expression and the contribution of RI were assayed in vivo. After administration of hematopoietic cells carrying the ri gene, mice were implanted with B16 melanomas for 21 days. The results showed that tumors of control groups became large and well vascularized. In contrast, tumors from mice groups treated with hematopoietic cells carrying the ri gene were small and possessed a relatively low density of blood vessels. The inhibited growth rate of the tumors was 47%. This study demonstrated the potential utility of gene therapy for systemic delivery of a novel antiangiogenic agent -hRI.

show abstract

Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells

Cited by 887 publications

References 34 publications

Chorioallantoic membrane capillary bed: A useful target for studying angiogenesis and anti‐angiogenesis in vivo

Chorioallantoic membrane capillary bed: A useful target for studying angiogenesis and anti‐angiogenesis in vivo

Platelet-derived growth factor and vascular endothelial growth factor expression in disc herniation tissue: an immunohistochemical study

Anti-tumor effect of hematopoietic cells carrying the gene of ribonuclease inhibitor

Contact Info

Product

Resources

About